AMENDMENTS TO THE CLAIMS

Please amend claims 10-12, cancel claims 1-9 and 20-28, and add new claims 29-33 as follows.

Claims 1-9 (Canceled).

10. (Original) A method of treating a ~~condition~~ cancer regulated by HER-kinase axis activation that is resistant to therapeutic treatments directed exclusively at either the PPAR-gamma pathway or the HER-kinase axis in a mammal, comprising:

administering a quantity of a non-steroidal anti-inflammatory drug (NSAID) that modulates the PPAR-gamma pathway to said mammal on a NSAID periodic basis; and

administering a quantity of a HER-kinase axis inhibitor to said mammal on a HER-kinase axis inhibitor periodic basis to treat the cancer.

11. (Currently Amended) The method of claim 10, wherein the NSAID is selected from the group consisting of aspirin, diclofenac, diflunisal, etodolac, fenoprofen, floctafenine, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sunlindac, tenoxicam, tiaprofenic acid, tolmetin, ~~derivatives thereof, analogs thereof, pharmaceutical equivalents thereof,~~ and combinations thereof.

12. (Currently Amended) The method of claim 10, wherein the HER-kinase axis inhibitor is selected from the group consisting of recombinant humanized monoclonal antibody 2C4, ansamycins, gefitinib, erlotinib, monoclonal antibodies, rapamycin, src inhibitors, tyrosine kinase inhibitors, compound LY294002, imatinib mesylate, trastuzumab, compound CI 1033, compound Psi 166, compound GW2016, compound EKB569, compound IMC-C225, ~~and derivatives thereof, analogs thereof, pharmaceutical equivalents thereof,~~ and combinations thereof.

13. (Original) The method of claim 10, wherein said NSAID is R-etodolac.

14. (Original) The method of claim 10, wherein said HER-kinase axis inhibitor is recombinant humanized monoclonal antibody 2C4.

15. (Original) The method of claim 10, wherein the quantity of said NSAID is from about 100 to about 500 mg/kg of said mammal.

16. (Original) The method of claim 10, wherein the quantity of said HER-kinase axis inhibitor is from about 5 to about 40 mg/kg of said mammal.

17. (Original) The method of claim 10, wherein the HER-kinase axis inhibitor periodic basis is twice weekly.

18. (Original) The method of claim 10, wherein the NSAID periodic basis is daily.

19. (Original) The method of claim 10, wherein administering said quantity of said NSAID and administering said quantity of said HER-kinase axis inhibitor further comprises using a delivery technique independently selected from the group consisting of intraperitoneal, oral gavage, intravenous, sublingual, topical, intramuscular, intra-arterial, intramedullar, intrathecal, intraventricular, transdermal, subcutaneous, intranasal, parenteral, and rectal.

Claims 20-28 (Canceled).

29. (New) The method of claim 10, wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, lung cancer, ovarian cancer, brain cancer, colon cancer, and combinations thereof.

30. (New) The method of claim 29, wherein the cancer is prostate cancer.

31. (New) A method of treating prostate cancer in a mammal, comprising:

administering a quantity of R-etodolac on an R-etodolac periodic basis; and

administering a quantity of a recombinant humanized monoclonal antibody 2C4 to said mammal on a 2C4 periodic basis.

32. (New) The method of claim 31, wherein the 2C4 periodic basis is twice weekly.

33. (New) The method of claim 31, wherein the R-etodolac periodic basis is daily.